Aptorum Group Limited (NASDAQ:APM) Sees Large Decline in Short Interest

Aptorum Group Limited (NASDAQ:APM) was the recipient of a large decrease in short interest in the month of September. As of September 30th, there was short interest totalling 2,200 shares, a decrease of 47.6% from the September 15th total of 4,200 shares. Currently, 0.1% of the shares of the company are sold short. Based on an average daily volume of 15,400 shares, the days-to-cover ratio is presently 0.1 days.

Hedge Funds Weigh In On Aptorum Group

A hedge fund recently bought a new stake in Aptorum Group stock. Murchinson Ltd. acquired a new position in Aptorum Group Limited (NASDAQ:APM) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 14,000 shares of the company’s stock, valued at approximately $133,000. Murchinson Ltd. owned 0.27% of Aptorum Group at the end of the most recent quarter. Institutional investors own 3.80% of the company’s stock.

Aptorum Group Price Performance

APM opened at $1.69 on Friday. The business has a 50 day moving average of $2.58 and a 200-day moving average of $4.31. Aptorum Group has a 1-year low of $1.35 and a 1-year high of $17.49.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.